icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
X2Q8tL0MHELYKMse